Mosaic’s Q2 Earnings Dip Defies Rising Price Targets

Sunday, Aug 2, 2026 2:13 am ET2min read
MOS--
Aime RobotAime Summary

- Mosaic’s Q2 2026 EPS forecast drops to $0.08, far below Q1’s $0.20, signaling near-term margin pressures and operational volatility.

- Q1 revenue hit $3B (beating estimates) but net income fell to -$254.5M, highlighting cost challenges despite top-line growth.

- Analysts project 2026 full-year EPS recovery to $0.92 and 134% growth to $1.71 in 2027, supported by raised price targets from RBC ($45) and BarclaysBCS-- ($46).

- Debt financing and dividend stability offset short-term risks, though Q2 phosphate sales declines and trailing P/E of 170x warrant caution.

Forward-Looking Analysis

Wall Street analysts project Mosaic’s Q2 2026 earnings per share (EPS) to reach $0.08, a significant decline from the Q1 consensus of $0.20. This estimate is based on a single analyst forecast, indicating limited coverage and potentially higher uncertainty for this quarter. The consensus reflects a cautious outlook, especially following Q1’s substantial miss where reported EPS was $0.05 against a $0.20 estimate. While Q1 revenue came in at $3.00 billion, slightly above the $2.93 billion estimate, the earnings miss suggests margin compression or higher costs. For the full year 2026, analysts estimate EPS of $0.92, implying a recovery trajectory through Q3 ($0.28) and Q4 ($0.34). However, the Q2 estimate of $0.08 remains the lowest in the quarterly sequence for 2026, signaling near-term profitability challenges. Long-term projections are more optimistic, with EPS expected to grow 134.25% to $1.71 in 2027. Analyst price targets have been recently raised by institutions like RBC Capital to $45 and Barclays to $46, reflecting confidence in the company's long-term fundamentals despite the near-term earnings weakness.

Historical Performance Review

Mosaic delivered a mixed Q1 2026 performance, posting revenue of $3.00 billion, which beat the $2.93 billion consensus. However, profitability suffered significantly, with net income dropping to -$254.50 million and GAAP EPS missing expectations at -$0.81, compared to the $0.05 reported figure. Gross profit stood at $235.60 million, indicating pressure on margins despite top-line growth. This result followed a Q4 2025 miss of $0.26 and a Q3 2025 beat of $0.01, highlighting volatility in earnings execution. The trailing P/E ratio of 170.00 underscores the stretched valuation relative to recent earnings, while the forward P/E of 30.27 suggests anticipated improvement. The company’s ability to stabilize net income and EPS is critical for restoring investor confidence after the sharp Q1 decline.

Mosaic recently completed a $900 million senior notes offering in November 2025, strengthening its balance sheet. The company declared a quarterly dividend of $0.22 per share, yielding 3.6%, with payments scheduled for December 18, 2025. Analyst sentiment has been mixed but generally positive on valuation; RBC Capital raised its price target to $45 from $40, and Barclays increased its target to $46 from $40, while maintaining Buy ratings. Conversely, Wells Fargo assumed coverage with an Equal Weight rating and a $28 target, and Berenberg Bank issued a Hold rating. Recent stock movement included a 5.7% drop in June 2025 after the company lowered Q2 phosphate sales volumes. Executive activity included significant stock sales by CEO Precourt III and other executives in early 2025. The company continues to operate through its Phosphates, Potash, and MosaicMOS-- Fertilizantes segments, focusing on global crop nutrient production.

Summary & Outlook

Mosaic’s financial health shows revenue resilience but faces margin pressures, evidenced by Q1’s negative net income. The primary risk is near-term earnings volatility, with Q2 estimates predicting a further dip in EPS to $0.08. However, the strong analyst consensus for full-year 2026 EPS growth and recent price target upgrades suggest underlying operational strength. The completion of debt offerings and consistent dividend payments indicate solid liquidity. While the Q1 miss and volume reductions pose short-term headwinds, the projected 134% EPS growth in 2027 supports a neutral-to-bullish long-term stance. Investors should monitor Q2 gross margins and phosphate sales volumes for signs of stabilization. The stock’s high trailing P/E warrants caution, but the forward growth narrative remains intact.

Get noticed about the list of notable companies` earning reports after markets close today and before markets open tomorrow.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



No comments

No comments yet